Thermo Fisher Launches CTS Compleo Automated System To Transform Cell Therapy Fill-Finish Manufacturing
Thermo Fisher Scientific launches CTS Compleo automated system to streamline cell therapy fill-finish processes, reducing variability and improving GMP-compliant manufacturing efficiency
Breaking News
Apr 03, 2026
Vaibhavi M.
Thermo Fisher Scientific Inc. has announced the global launch of the Gibco™ CTS™ Compleo™ Fill and Finish System, an automated and functionally closed solution designed to simplify formulation and filling processes in cell therapy manufacturing. The system aims to reduce operational risks and improve efficiency by replacing labour-intensive manual workflows with streamlined automation.
Cell therapy production presents unique challenges, particularly due to the variability of patient-derived starting materials, including cell count, viability, and concentration. As more therapies move closer to commercialisation, manufacturers are increasingly seeking solutions that minimise manual handling while maintaining strict standards for sterility, dosing precision, and product consistency. Early adopters of the CTS Compleo system have already reported improvements in reducing variability and enhancing manufacturing workflows.
“We’re excited to bring forward a solution that addresses one of the biggest bottlenecks in cell therapy manufacturing, manual fill and finish,” said Tiffani Manolis, vice president and general manager, cell biology, Thermo Fisher Scientific. “By combining automation with a functionally closed design, the Gibco CTS Compleo system has the ability to streamline workflows, improve consistency and help customers accelerate the delivery of life-changing therapies to patients.”
Traditionally, formulation and filling processes rely heavily on manual handling of delicate cells in small volumes, which can introduce contamination risks and inconsistencies. The CTS Compleo system addresses these issues with a compact, automated setup that ensures a closed processing environment, enabling consistent performance across batches while minimising human intervention.
“As we continue advancing our cell therapy programs, scalable and automated closed-system manufacturing solutions are a key priority,” said Ryan Zapata, Sr. Process Engineer at Arsenal Biosciences, Inc. “The Compleo system offers a platform for closed formulation and fill that can be easily integrated into existing autologous cell therapy processes. The intuitive protocol builder software allows for flexibility and rapid iteration in the development environment, enabling use across programs.”
The system is part of Thermo Fisher’s broader Gibco™ Cell Therapy Systems (CTS™) portfolio, which includes instruments, reagents, software, and viral vector solutions to support end-to-end GMP-compliant manufacturing. In addition, the company offers comprehensive implementation support, including installation, process development, and global service coverage, helping manufacturers seamlessly integrate the system into their operations.
Also Read
